1228 (1228) Fair Value & Analysis

Healthcare · Market cap HK$1.1B

1 1228 1228 · HK

PriceHK$2.70

Fair ValueHK$1.17

Upside-56.7%

Quality58/100

Evidence: Medium Range HK$0.8200 – HK$1.52

Fair value as of: Jul 2, 2026

From 10 valuation models · updated today

Share price +33.0% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.2800 – HK$3.15 · fair‑value band HK$0.8200 – HK$1.52 · the HK$2.70 price screens above the HK$1.17 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1228 (1228) currently trades at HK$2.70, while our model-based Fair Value estimate is HK$1.17 — implying the stock looks roughly 56.7% overvalued today. We read business quality at 58/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, 1228 generated revenue of HK$50.0M at a net margin of 29.7%. Revenue declined 31.2% year over year. The balance sheet holds a net cash position of HK$50.6M. The stock trades on a trailing P/E of 70.3. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$50.0M

Revenue growth (YoY) -31.2%

Net margin 29.7%

Return on equity -282%

Free cash flow −HK$38.2M FY2025

P/E ratio 70.3

More key figures

Operating margin -180%

EPS (TTM) HK$0.1400

Net cash HK$50.6M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1228 reported revenue of HK$50.0M in FY2025 versus HK$31.2M in FY2021, a compound +12.5%/yr. Reported net income was HK$14.8M in FY2025.

Revenue +12.5%/yr

FY21 HK$31.2M

FY22 HK$79.0M

FY23 HK$103M

FY24 HK$85.1M

FY25 HK$50.0M

Net income

FY21 −HK$1.1B

FY22 −HK$483M

FY23 −HK$379M

FY24 −HK$443M

FY25 HK$14.8M

Is 1228 fairly valued? → Check now

Similar stocks

6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	7,746 MXN	5,617 MXN	-27%
Regeneron Pharmaceuticals, Inc REGN	$635.45	$547.01	-14%
UCB SA UCB	€247.60	€180.06	-27%
argenx SE ARGNF	$900.00	$382.64	-57%
Alnylam Pharmaceuticals, Inc ALNY	$286.41	$106.81	-63%
Samsung Biologics Co 207940	1,000,000 KRW	1,091,384 KRW	+9%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1228 (1228) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$1.17 versus a price of HK$2.70 — about −57% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 1228?

Our model-based fair value for 1228 is HK$1.17 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$2.70.

What is the quality score of 1228?

1228 has a Quality Score of 58/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1228 (1228)?

1228 reported trailing-twelve-month revenue of about HK$50.0M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1228?

The net profit margin of 1228 is about 29.7%, meaning it keeps roughly 29.7% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.